Ventilator-associated pneumonia (VAP) Companies

Pulmonetics acquires VAP detection startup, RespiraTech deal strengthens Pulmonetics' offerings with RespiraTech's AI-powered early VAP detection technology, aiming to prevent infections before they arise.

Roche partners with Veridian Medical collaboration combines Roche's diagnostic expertise with Veridian's continuous glucose monitoring technology, potentially leading to new tools for monitoring patients at risk of VAP.

Vapotherm and PulmoTech are developing breathalyzer-like devices for rapid and non-invasive VAP diagnosis, reducing reliance on invasive procedures.

Sepsis.io and EarlySight are utilizing AI to analyze patient data and predict VAP risk, enabling proactive interventions like personalized ventilation settings.

List of Ventilator associated pneumonia Key Companies in the Market

• Adenium Biotech ApS (Denmark)


• Merck & Co. Inc. (US)


• AstraZeneca (UK)


• MedImmune (US)


• Nabriva Therapeutics AG (Ireland)


• Thermo Fisher Scientific (US)


• Bayer AG (Germany)


• Wockhardt (India)


• Shionogi Inc. (Japan)


• Cardeas Pharma (US)